ASH Conference 2023-
Patient Coverage

Explore the latest breakthroughs in blood cancer clinical trials, research, and treatments that patients need to know from ASH, the American Society of Hematology’s Annual Meeting and Exposition 2023.


Should Cancer Patients Reconsider CAR T-cell Therapy amid FDA investigation?

Get your questions about CAR T-cell therapy by Dr. Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, at the ASH conference in San Diego 2023.

Dr. Brody addresses pertinent questions about CAR T-cell therapy. Given the ongoing evaluation of the identified risk of T-cell malignancy and the potential serious outcomes, including hospitalization and death, patients and their caregivers must stay updated.

ASH Conference 2023
News & Interviews by Cancer Type


Should Cancer Patients Reconsider CAR T-cell Therapy?

Should Cancer Patients Reconsider CAR T-cell Therapy? Explore CAR T-cell therapy insights with Dr. Joshua Brody amid FDA investigation. The headlines about the recent FDA investigation into CAR T-cell...

Multiple Myeloma

Significant Disparity: Myeloma Real-World Results Show Striking Contrast with Clinical Trials

Worse Outcomes for Myeloma Patients in Real-World Results vs. Clinical Trials Multiple myeloma patient outcomes are strikingly different in the real-world versus controlled environments according to...